Comparing Ultra High-Resolution CT to Conventional CT for Heart Disease
Ultra-High Resolution Computed Tomography (CT) vs. Conventional CT for Detecting Obstructive Coronary Artery Disease (CAD) The CORE-COMPARE Pilot Study
NA · Johns Hopkins University · NCT06170541
This study is testing whether a new type of heart scan called Ultra High-Resolution CT can find heart disease better than the regular CT scan in people who are at lower risk.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 21 Years to 85 Years |
| Sex | All |
| Sponsor | Johns Hopkins University (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT06170541 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Ultra High-Resolution Computed Tomography (UHR-CT) compared to conventional CT in identifying obstructive coronary heart disease (CHD) in a lower-risk population. Participants will undergo a single scan using UHR-CT, which allows for the reconstruction of conventional resolution images from the same data, minimizing radiation exposure and scan time. The primary goal is to gather preliminary data to support the hypothesis that UHR-CT is superior in detecting CHD. This approach aims to justify the broader implementation of UHR-CT technology in clinical practice.
Who should consider this trial
Good fit: Ideal candidates are adults aged 21-85 with a clinical history suggestive of coronary heart disease referred for further evaluation via CT angiography.
Not a fit: Patients with known allergies to iodinated contrast media or severe heart conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved noninvasive detection of coronary heart disease, enhancing patient outcomes.
How similar studies have performed: While the specific use of UHR-CT in this context is novel, similar studies have shown promise in improving imaging techniques for cardiovascular conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 21-85 years * Clinical history suggestive of CHD who are referred by their primary cardiologist for further evaluation via Computed tomography angiography (CTA) will be asked to participate. * Women of child bearing potential must demonstrate a negative pregnancy test within 24 hours of the study CTA. * Ability to understand and willingness to sign the Informed Consent Form. Exclusion Criteria: * Known allergy to iodinated contrast media. * History of multiple myeloma or previous organ transplantation * Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula * Atrial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block) * Evidence of severe symptomatic heart failure (NYHA Class III or IV); * Known or suspected moderate or severe aortic stenosis * History of prior percutaneous coronary intervention (PCI) in one or more vessel or history of coronary arterial bypass grafting (CABG) * Suspected acute coronary syndrome * Presence of any other history or condition that the investigator feels would be problematic
Where this trial is running
Baltimore, Maryland
- Johns Hopkins School of Medicine — Baltimore, Maryland, United States (RECRUITING)
Study contacts
- Principal investigator: Joao Lima, Professor — MD
- Study coordinator: Joao Lima, Professor
- Email: jlima@jhmi.edu
- Phone: 4106141284
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Coronary Heart Disease